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Background: To identify the predictive factors for malignancies using basic clinical and laboratory information in
children presenting with musculoskeletal pain and eventually diagnosed with juvenile idiopathic arthritis (JIA) or
malignancy.
Methods: A retrospective case–control chart review research examining laboratory data from patients referred for
musculoskeletal pain in 2001–2010 and diagnosed with malignancy or JIA was performed. The validity of each test
for the diagnosis of neoplasia was assessed by calculating the sensitivity, specificity, positive predictive values (PPV),
negative predictive values (NPV) and likelihood ratios.
Results: A total of 134 patients were enrolled. Statistically significant differences were found in neutrophil count,
Hb, LDH, IgA and C4 values, ANA, anti-EA EBV IgG and anti-CMV IgG titres. High LDH value and anti-CMV IgG were
the most predictive factors for neoplasia. High specificity factors for neoplasia were abnormal values of neutrophil
count, Hb, IgA and C4, and the presence of anti-EA EBV and anti-CMV IgG. High PPV were recorded for abnormal
neutrophil count, Hb value and anti-CMV titre. A low NPV was found only for anti-EA EBV and anti-CMV titres.
Conclusions: In this setting of patients, minimum changes in neutrophil count, particularly if associated with low
Hb and high LDH levels, are to be thoroughly considered, because they appear as the most predictive factors for
the diagnosis of tumour.
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White blood cell countBackground
Musculoskeletal pain is a common symptom in children,
and in some cases it is the first sign of a severe disease
such as chronic inflammatory disease or a malignancy
[1-4]. About 15% to 30% of children with acute lym
phoblastic leukaemia (ALL), the commonest childhood
malignancy, and most patients with disseminated neuro-
blastoma report joint and/or bone symptoms [2-4]. In a
child with leukaemia, musculoskeletal pain is normally
accompanied by other clinical, laboratory and imaging
data that easily indicate the diagnosis. Only in very few* Correspondence: adicata@unict.it
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reproduction in any medium, provided the orcases this sign is isolated, which complicates the diagnosis
[2,4]. On the other hand, in the absence of patognomonic
tests the diagnosis of juvenile idiopathic arthritis (JIA) is
the result of an integrative analysis of several data exclu-
ding other potential aetiologies of the pain and satisfying
the established criteria [5]. Adult patients are able to guide
the physician to the right diagnosis since they can tho-
roughly depict the characteristics of the pain. Conversely,
a child can hardly describe it clearly.
In this particular setting, the insidious onset and the
lack of typical signs and laboratory tests may delay ma-
lignancy diagnosis in children [5,6]. Another risk is mis-
diagnosis, like JIA, and the consequent administration of
corticosteroids leading to further delays and wrong treat-
ments [6].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to those with JIA for the pattern of initial findings is li-
mited and involves small series of patients [7-9] and to
translate results into optimal clinical practice is crucial:
this is the reason why we undertook this retrospective
analysis.
In order to improve the quality of clinical practice and
patient outcomes, the aim of our study was to identify
the predictive factors for malignancies using basic cli-
nical and laboratory information in children presenting
with musculoskeletal pain and eventually diagnosed with
JIA or malignancy.
Methods
The study is a retrospective case–control chart review
research examining both clinical and laboratory data
from the initial visit of all the patients referred for
musculoskeletal pain to the Department of Paediatrics of
the University of Catania during the period January
2001–December 2010 and diagnosed with a neoplastic
disease or JIA. We included patients with neoplasia and
patients with JIA, already diagnosed, and retrospectively
reviewed their charts in order to evaluate all relevant
clinical and laboratory data. Patients with blast cells in
the blood smear were excluded.
The study has been approved by the Institutional
Review Board of our Department of Pediatrics.
Information regarding demographic data, symptoms,
clinical manifestations, diagnosis, outcome and labora-
tory data were collected from the clinical records.
Statistical analyses were performed using the software
SPSS version 14.0 (SPSS, Chicago, IL, USA). Percentage
was used to describe categorical variables, while con-
tinuous variables were described by mean and range.
Statistical comparison of proportions was performed by
χ2 test; statistical comparison of continuous variables
was carried out by Student’s t-test. Basic significance
level was fixed at p <0.05. The value of the given diag-
nostic test as a predictive factor for neoplasia in com-
parison to JIA and for ALL in comparison to JIA were
assessed among groups, only for significantly different
variables (p <0.05), by calculating sensitivity, specificity,
positive predictive value (PPV), negative predictive value
(NPV), positive and negative likelihood ratios (LR+ and
LR- respectively). In particular, for each diagnostic test,
sensitivity was determined by calculating the proportion
of the number of true positive patients among all
patients with the disease (i.e. true positives and false
negatives); specificity was determined by calculating the
proportion of the number of true negative patients
among all healthy patients (i.e. true negatives and false
positives); PPV was determined by calculating the
proportion of the number of true positive patients
among all positive patients (i.e. true positives and falsepositives); NPV was determined by calculating the
proportion of the number of true negative patients
among all negative patients (i.e. true negatives and false
negatives); the LR+ was computed as the sensitivity
divided by 1–specificity and the LR- as 1–sensitivity
divided by specificity. The differences in the denomina-
tors were the result of missing data for the variable
analyzed.
Results
During the ten-year study a total of 150 patients hospita-
lised because of musculoskeletal pain were eventually
diagnosed with JIA (n = 71) or malignancy (n = 79). Six-
teen out of the 79 children with malignancy were
excluded because blast cells were shown in the blood
smear, so 134 patients (63 with malignancy and 71 with
JIA) were finally enrolled in the study. Their main char-
acteristics are shown in Table 1. ALL was the most fre-
quent neoplasia type and oligoarticular JIA the most
frequent JIA subtype. Age and gender distributions were
similar in the two groups.
Normal reference laboratory values, relative to the li-
mits of the norm of our Institution, are indicated in
Table 2 together with the number and percentage of
patients with low and high values for each laboratory
test, both for the neoplasia and the JIA groups. Further-
more, the comparison of laboratory tests as diagnostic
markers of patients in the neoplasia group and in the
JIA group, considered as absolute number and percen-
tage of patients with abnormal values, is reported in
Table 3. Statistically significant differences in the neopla-
sia and the JIA groups were found between the following
parameters: neutrophils count, haemoglobin (Hb), lac-
tate dehydrogenase (LDH), IgA and C4 subunit of com-
plement (C4) values, antinuclear antibodies (ANA),
anti-early antigen (EA) Epstein-Barr virus (EBV) IgG
and anti-cytomegalovirus (CMV) IgG titres. No signifi-
cant differences were found in the other parameters
under evaluation and for calcium, phosphorus, anti-
muscle antibodies (AMA) and anti-smooth muscle anti-
bodies (ASMA). High LDH value and positivity to
anti-CMV IgG were the most predictive factors for neo-
plasia (sensitivity >70%). High specificity (≥ 80%) for
neoplasia was shown by the following factors: abnormal
values of neutrophil count, Hb, IgA and C4, and the
presence of anti-EA EBV and anti-CMV IgG. High PPVs
(≥ 85%) were recorded for abnormal neutrophil count,
Hb value and anti-CMV IgG titre. A low NPV (< 50%)
was found only for anti-EA EBV and anti-CMV IgG
titres. Neutrophils count, Hb, IgA, C4 and anti-CMV
IgG titre, shown high LR+ values (>2).
The combination of all three abnormal values in
neutrophil count, Hb and LDH provide an increase in
sensitivity (93.3%) and in specificity (100%).








Mean age in months (range) 92.2 (3–203) 92.6 (3–203) 91.9 (15–198)
Female 57.5% 52.4% 62.0%
Neoplasia types
- ALL 47 74.6%
- Lymphomas 4 6.3%
- Other neoplasia 12 19.1%
JIA subtypes
- systemic 18 25.4%
- polyarthritis 15 21.1%
- oligoarticular 36 50.7%
- psoriasis 1 1.4%
- other 1 1.4%
Agodi et al. BMC Pediatrics 2013, 13:15 Page 3 of 7
http://www.biomedcentral.com/1471-2431/13/15Table 4 reports the results of diagnostic markers,
considered as number and percentage of patients with
abnormal values, among patients with ALL compared
with those of patients with JIA. Statistically significant
differences were found between the two groups with
regard to neutrophil count, Hb, IgA and C4 values,
ANA, anti-EA EBV and anti-CMV IgG titres. No sig-
nificant differences were found in the abnormal values
of the other parameters under evaluation and for cal-
cium, phosphorus, AMA and ASMA. The most pre-
dictive factors for ALL were as follows: with high
sensitivity (>70%) positivity to anti-CMV IgG only;
with high specificity (≥80%), neutrophil count, Hb
value, IgA, C4, anti-EA IgG and anti-CMV IgG titres.
High PPVs (>80%) were recorded for neutrophil
count, Hb value and anti-CMV IgG titre. NPVs were
low (<50%) for anti-EA IgG titre. Neutrophils count,
Hb, IgA, C4 and anti-CMV IgG titre, shown high LR+
values (>2).
Comparing patients with ALL to those with JIA, the
combination of both abnormal values of neutrophil
count and Hb did not show any increase in sensitivity
(46.8%), whereas an increase in specificity was observed
(98.5%).
As far as clinical data are concerned, monolateral
and bilateral musculoskeletal pain were observed with
similar frequency in children with JIA (32.4% and
38.0% respectively) and in children with neoplasia
(31.7% and 38.1% respectively). Furthermore, fever
was significantly more recurrent in children with neo-
plasia (71.4%) as compared to children with JIA
(33.8%) (p = 0.000). Finally, lymphadenopathy was
significantly more frequent in children with neoplasia
(23.8%) than in children with JIA (7.0%) (p = 0.007).Discussion
Musculoskeletal pain is a frequent complaint among
children but only in few cases it implies severe diseases
such as malignancies or chronic inflammatory diseases.
Only in very few cases musculoskeletal pain is an iso-
lated sign hindering the formulation of the diagnosis. In
some of those cases general practitioners or paediatri-
cians address the patient to the rheumatologist or the
orthopaedist who tend to consider musculoskeletal
symptoms as a sign of a chronic inflammatory disease.
Therefore they prescribe analyses in order to validate
their clinical hypothesis or start treatment without a
clear diagnosis. In such a case, treatment with corticos-
teroids relieves symptoms thus causing a further delay in
the diagnosis. Even when both diagnostic hypotheses are
included, it can be hard to distinguish the clinical signs
of JIA from malignancies because symptoms at the onset
may be the same [3,9]. Moreover, in the absence of pa-
thognomonic test the diagnosis of JIA requires the ex-
clusion of all the other causes of musculoskeletal pain.
Furthermore, when no haematological signs are present,
even leukaemia or a tumour could be difficult to detect.
This clinical overlapping explains the need to always
exclude a malignancy in children with musculoskeletal
symptoms, especially when the clinical pattern is not
characteristic of a specific rheumatic disease and/or in
the presence of organomegaly or abnormal laboratory or
imaging data.
A limited number of studies have been conducted in
order to examine the value of diagnostic markers in the dif-
ferential diagnosis between JIA and malignancies in chil-
dren [7-9] and results are often inconsistent. In order to
identify early parameters useful for a differential diagnosis,
clearly defining the role of laboratory tests in terms of usage
within the clinical diagnostic algorithms and the patient
population for whom they are intended, in the present
study we retrospectively evaluated ten-years data of two dif-
ferent groups of children with musculoskeletal pain, one
affected by tumour and the other by JIA. No significant dif-
ference was found between the two groups for sex and age
at the time of the diagnosis. High C-reactive protein (CRP)
and erythrocyte sedimentation rate (ESR) were not relevant
parameters, being CRP slightly higher among the JIA
group, but with no statistically significant difference. Some
authors suggest taking the neutrophil count carefully into
consideration in a child complaining musculoskeletal pain
[2,9]. Our results confirm a statistically significant differ-
ence in the neutrophil count between the two groups, being
lower values significantly most frequent among patients
with tumour (45.5% vs 3.3%) or leukaemia (52.5%), with
high specificity, PPV and LR+, but low sensitivity. This
means that a normal result of this test is very frequent
among “non tumour” patients even though an altered result
is not a clear sign of a “tumour/leukaemia” patient.





Neoplasia (N=63) JIA (N=71)












WBC count 4-10 × 109/L 11/60; 18.3% 27/60; 45% 22/60; 36.7% 3/68; 4.4% 35/68; 51.5% 30/68; 44.1%
Neutrophil count 1 × 109/L 25/55; 45.5% 30/55; 54.5% 0/55; 0% 2/61; 3.3% 59/61; 96.7% 0/61; 0%
Platelet count 150-300 ×
109/L
34/60; 56.7% 13/60; 21.7% 13/60; 21.7% 2/68; 2.9% 17/68; 25% 49/68; 72.1%
Hemoglobin (Hgb) ≥10 gr/dl 34/60; 56.7% 26/60; 43.3% NA 62/68; 91.2% 6/68; 8.8% NA
Lactic dehydrogenase
(LDH)
<500 IU/L NA 7/58; 12.1% 51/58; 87.9% NA 16/49; 32.7% 33/49; 67.3%
Erythrocyte sedimentation
rate (ESR)
<20 mm/h NA 4/37; 10.8% 33/37; 89.2% NA 14/68; 20.6% 54/68; 79.4%
C-reactive protein (CRP) <1 mg/dl NA 13/52; 25% 39/52; 75% NA 14/61; 23% 47/61; 77%
Antinuclear antibody (ANA) ≥1:80 NA 16/19; 84.2% 3/19; 15.8% NA 30/62; 48.4% 32/62; 51.6%
IgG 751–1560
mg/dl
9/51; 17.6% 35/51; 68.6% 7/51; 13.7% 2/57; 3.5% 35/57; 61.4% 20/57; 35.1%
IgM 46–304 mg/
dl
4/51; 7.8% 47/51; 92.2% 0/51; 0% 1/57; 1.8% 53/57; 93% 3/57; 5.3%
IgA 82–453 mg/
dl
17/51; 33.3% 33/51; 64.7% 1/51; 2% 6/57; 10.5% 49/57; 86% 2/57; 3.5%
C3 79–152 mg/
dl
1/36; 2.8% 14/36; 38.9% 21/36; 58.3% 3/54; 5.6% 29/54; 53.7% 22/54; 40.7%
C4 16–38 mg/
dl
1/36; 2.8% 19/36; 52.8% 16/36; 44.4% 4/53; 7.5% 44/53; 83% 5/53; 9.4%
Anti-EBV IgM Negative NA 37/44; 84.1% 7/44; 15.9% NA 13/14; 92.9% 1/14; 7.1%
Anti-EBV IgG Negative NA 11/44; 25% 33/44; 75% NA 7/15; 46.7% 8/15; 53.3%
Anti-EA EBV IgG Negative NA 21/35; 60% 14/35; 40% NA 10/10; 100% 0/10; 0%
Anti-CMV IgM Negative NA 32/34; 94.1% 2/34; 5.9% NA 8/10; 80% 2/10; 20%

















Table 3 Comparison of abnormal values of diagnostic markers between neoplasia and JIA patients
Diagnostic markers All patients n/N (%) Neoplasia n/N (%) JIA n/N (%) p-value (Neoplasia versus JIA) Sensitivity Specificity PPV NPV LR+ LR-
WBC count 66/128 (51.6) 33/60 (55.0) 33/68 (48.5) 0.484
Neutrophil count 27/116 (23.3) 25/55 (45.5) 2/61 (3.3) 0.000 45.5% 96.7% 92.5% 66.2% 13.8 0.6
Platelet count 98/128 (76.6) 47/60 (78.3) 51/68 (75.0) 0.682
Hb 40/128 (31.3) 34/60 (56.7) 6/68 (8.8) 0.000 56.7% 91.2% 85.0% 70.4% 6.4 0.5
LDH 84/107 (78.5) 51/58 (87.9) 33/49 (67.3) 0.017 87.9% 32.7% 60.7% 69.5% 1.3 0.4
ESR 87/105 (82.9) 33/37 (89.2) 54/68 (79.4) 0.281
CRP 86/113 (76.1) 39/52 (75.0) 47/61 (77.0) 0.828
ANA 35/81 (43.2) 3/19 (15.8) 32/62 (51.6) 0.008 15.8% 48.4% 8.5% 65.2% 0.3 1.7
IgG 38/108 (35.2) 16/51 (31.4) 22/57 (38.6) 0.545
IgM 8/108 (7.4) 4/51 (7.8) 4/57 (7.0) 1.000
IgA 26/108 (24.1) 18/51 (35.3) 8/57 (14.0) 0.013 35.3% 86.0% 69.2% 59.7% 2.5 0.8
C3 47/90 (52.2) 22/36 (61.1) 25/54 (46.3) 0.200
C4 26/89 (29.2) 17/36 (47.2) 9/53 (17.0) 0.004 47.2% 83.0% 65.3% 69.8% 2.8 0.6
Anti-EBV IgM 8/58 (13.8) 7/44 (15.9) 1/14 (7.1) 0.665
Anti-EBV IgG 41/59 (69.5) 33/44 (75.0) 8/15 (53.3) 0.192
Anti-EA EBV IgG 14/45 (31.1) 14/35 (40.0) 0/10 (0) 0.019 40.0% 100% 1.0% 32.2% - 0.6
Anti-CMV IgM 4/44 (9.1) 2/34 (5.9) 2/10 (20.0) 0.218

















Table 4 Comparison of abnormal values of diagnostic markers between ALL and JIA patients
Diagnostic markers All patients n/N (%) ALL n/N (%) JIA n/N (%) p-value
(ALL versus JIA)
Sensitivity Specificity PPV NPV LR+ LR-
WBC count 59/113 (52.2) 26/45 (57.8) 33/68 (48.5) 0.345
Neutrophil count 23/101 (22.8) 21/40 (52.5) 2/61 (3.3) 0.000 52.5% 96.7% 91.3% 75.6% 15.9 0.5
Platelet count 87/113 (77.0) 36/45 (80.0) 51/68 (75) 0.650
Hb 32/113 (28.3) 26/45 (57.8) 6/68 (8.8) 0.000 57.8% 91.2% 81.2% 76.5% 6.6 0.5
LDH 70/92 (76.1) 37/43 (86.0) 33/49 (67.3) 0.050
ESR 78/95 (82.1) 24/27 (88.9) 54/68 (79.4) 0.379
CRP 73/99 (73.7) 26/38 (68.4) 47/61 (77.0) 0.358
ANA 34/76 (44.7) 2/14 (14.3) 32/62 (51.6) 0.016 14.3% 48.4% 5.8% 71.4% 0.3 1.8
IgG 34/96 (35.4) 12/39 (30.8) 22/57 (38.6) 0.517
IgM 6/96 (6.3) 2/39 (5.1) 4/5 (7.0) 1.000
IgA 23/96 (24.0) 15/39 (38.5) 8/57 (14.0) 0.008 38.5% 86% 65.2% 67.1% 2.8 0.7
C3 42/82 (51.2) 17/28 (60.7) 25/54 (46.3) 0.250
C4 23/81 (18.4) 14/28 (50.0) 9/53 (17.0) 0.004 50% 83% 60.8% 75.8% 2.9 0.6
Anti-EBV IgM 8/50 (16.0) 7/36 (19.4) 1/14 (7.1) 0.414
Anti-EBV IgG 35/51 (68.6) 27/36 (75.0) 8/15 (53.3) 0.187
Anti-EA EBV IgG 12/40 (30.0) 12/30 (40.0) 0/10 (0) 0.019 40.0% 100% 1.0% 35.7% - 0.6
Anti-CMV IgM 4/40 (10.0) 2/30 (6.7) 2/10 (20.0) 0.256
Anti-CMV IgG 24/39 (61.5) 22/29 (75.9) 2/10 (20.0) 0.003 75.9% 80.0% 91.6% 53.3% 3.8 0.3
Agodi et al. BMC Pediatrics 2013, 13:15 Page 6 of 7
http://www.biomedcentral.com/1471-2431/13/15The same results were obtained for the haemoglobin
levels: anaemia (i.e. Hb <10 g/dl) was more frequently
found in the tumour group (56.7% vs 8.8%) or in the leu-
kaemia group (57.8%) with a statistically significant dif-
ference. However, it has been reported that anaemia
from chronic illness does occur in children with JIA and,
for this parameter, we found low sensitivity (56.7%) for
tumours. An abnormal platelet count was observed in
both groups of patients, with lower values among the
tumour group and higher values among the JIA group
(p <0.05).
According to literature, high LDH level proved a use-
ful predictive factor for tumours: abnormal values were
more prevalent among the tumour group (87.9% vs
67.3%; sensitivity 88.0%). In fact, as previously reported
in ALL patients [9], a twofold or even higher increase
was found exclusively among children with malignancies.
Consequently, if a child complains musculoskeletal pain,
high LDH level should be considered suspicious and it
requires further analyses to exclude a malignancy.
Moreover, in the comparison between the patients with
tumour and those with JIA, the combination of all three ab-
normal values in neutrophil count, Hb and LDH increased
sensitivity and specificity.
We also investigated clinical parameters like fever and
lymphadenopathy which resulted significantly more frequent
in patients with tumour despite a high number of missing
data. However, previous papers have already reported thelimited value of these clinical parameters for the comparison
of ALL and JIA [9-11].
Some diagnostic tests such as ANA and complement
have been reported as not meaningful to differentiate
tumours and JIA [9]. In our study the frequency of posi-
tive ANA patients was higher among the JIA group and
the difference was statistically significant, but this test
was characterized by low sensitivity and low specificity.
No significant difference in the other screened auto-
antibodies appeared between the two groups. Further-
more, no significant difference was detected in the
immunoglobulin profile even though we found abnormal
IgA values more frequently among the tumour group
and this result was statistically significant with high
specificity.
An odd result, seemingly difficult to comment, con-
cerns a positive anti-CMV IgG titre found more fre-
quently among patients with tumours than among JIA
patients, with a statistically significant difference and
with high specificity and high sensitivity, high PPV and
low NPV. Our data showed that the presence of these
antibodies is the most valid feature in patients with
tumour or leukaemia versus patients with JIA, although
the low number of tests taken in JIA patients makes the
numbers less reliable. Indeed, it has been reported
that leukemic patients have a higher titre of antibodies
against many herpes viruses than the healthy population
[12,13].
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In conclusion, our results suggest that even small changes
in the neutrophil count are of critical diagnostic value. In
cases where such alterations are associated with low Hb
levels and high LDH, the probability of a diagnosis of neo-
plasia is very elevated. Our study highlights the import-
ance of accurate diagnosis for the appropriate and
effective management to improve patient outcomes. Fur-
ther prospective studies considering a more numerous
sample would better evaluate the clinical utility of labora-
tory tests for the early differential diagnosis of leukaemia/
tumour or JIA.
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